CVS Caremark Reaches FTC Settlement on Drug Rebates, TrumpRx Coverage

CVS Health's (NYSE:CVS) Caremark unit has reached a settlement with the U.S. Federal Trade Commission (FTC) that will reshape some of its pharmacy benefit practices, specifically targeting drug rebates and the integration of the new TrumpRx discount platform. The agreement, announced Tuesday, aims to address practices regulators believe contribute to higher drug costs for consumers.

Key Terms of the Agreement

The settlement requires CVS Caremark, a major pharmacy benefit manager (PBM), to limit its use of after-market rebates, which are discounts negotiated with drug manufacturers after a sale. Critics of this model argue it can incentivize higher list prices.

Crucially, the agreement also mandates that Caremark must count consumer payments made through the TrumpRx.gov drug discount website toward their health plan deductibles. This provision concerning TrumpRx will take effect once the necessary supporting regulations for the program are finalized, according to the announcement.

Regulatory Scrutiny and Market Impact

FTC Chairman Andrew Ferguson said the settlement is expected to generate billions of dollars in savings on drug prices. He added that the FTC under the current administration "will not tolerate anticompetitive behavior that increases prices for American consumers."

Ad

This action is not an isolated event. The deal with CVS Caremark mirrors a similar agreement the FTC reached with Cigna earlier this year, signaling a broader regulatory focus on the business models of PBMs and their role in the pharmaceutical supply chain.

The Role of TrumpRx

Launched in February, the TrumpRx platform is designed to connect consumers, particularly those paying with cash, to discounted prices for both generic and branded drugs. The website has a notable focus on popular weight-loss medications from manufacturers like Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO).

A key limitation of the platform has been that its purchases operate outside of traditional insurance frameworks. This meant consumers' out-of-pocket spending on TrumpRx did not help them meet their annual deductibles, a barrier the new settlement aims to remove.